BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation. Int J Mol Sci 2020;21:E1391. [PMID: 32092903 DOI: 10.3390/ijms21041391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiang M, Wu X, Jing H, Liu L, Wang C, Wang Y, Novakovic VA, Shi J. The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors. Front Immunol 2022;13:955654. [DOI: 10.3389/fimmu.2022.955654] [Reference Citation Analysis]
2 Alomair BM, Al-kuraishy HM, Al-gareeb AI, Al-hamash SM, De Waard M, Sabatier J, Saad HM, El-saber Batiha G. Montelukast and Acute Coronary Syndrome: The Endowed Drug. Pharmaceuticals 2022;15:1147. [DOI: 10.3390/ph15091147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen Z, Wang G, Xie X, Liu H, Liao J, Shi H, Chen M, Lai S, Wang Z, Wu X. Ginsenoside Rg5 allosterically interacts with P2RY12 and ameliorates deep venous thrombosis by counteracting neutrophil NETosis and inflammatory response. Front Immunol 2022;13:918476. [DOI: 10.3389/fimmu.2022.918476] [Reference Citation Analysis]
4 Pintaningrum Y, . V, Dewi IP, Putra HBP, Mappangara I, Amir M, Yusuf I, Bukhari A. CYP2C19 polymorphism and coronary in-stent restenosis: A systematic review and meta-analysis. F1000Res 2022;11:346. [DOI: 10.12688/f1000research.109321.2] [Reference Citation Analysis]
5 Yuan F, Cai JN, Dai M, Lv X. Inhibition of P2Y6 receptor expression in Kupffer cells alleviates alcoholic steatohepatitis in mice. Int Immunopharmacol 2022;109:108909. [PMID: 35700583 DOI: 10.1016/j.intimp.2022.108909] [Reference Citation Analysis]
6 Mortazavi-Jahromi SS, Aslani M. Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation. Int Immunopharmacol 2022;110:109040. [PMID: 35839566 DOI: 10.1016/j.intimp.2022.109040] [Reference Citation Analysis]
7 Tesei A, Cortesi M, Bedeschi M, Marino N, Rossino G, Listro R, Rossi D, Linciano P, Collina S. Repurposing the Antiplatelet Agent Ticlopidine to Counteract the Acute Phase of ER Stress Condition: An Opportunity for Fighting Coronavirus Infections and Cancer. Molecules 2022;27:4327. [DOI: 10.3390/molecules27144327] [Reference Citation Analysis]
8 Yang Y, Liu H, Cui L, Liu Y, Fu L, Li B. A Collagen-Derived Oligopeptide from Salmo salar Collagen Hydrolysates Restrains Atherogenesis in ApoE-/- Mice via Targeting P2 Y12 Receptor. Mol Nutr Food Res 2022;:e2200166. [PMID: 35490399 DOI: 10.1002/mnfr.202200166] [Reference Citation Analysis]
9 Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V. The Purinergic Landscape of Non-Small Cell Lung Cancer. Cancers (Basel) 2022;14:1926. [PMID: 35454832 DOI: 10.3390/cancers14081926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pintaningrum Y, . V, Dewi IP, Putra HBP, Mappangara I, Amir M, Yusuf I, Bukhari A. CYP2C19 polymorphism and coronary in-stent restenosis: A systematic review and meta-analysis. F1000Res 2022;11:346. [DOI: 10.12688/f1000research.109321.1] [Reference Citation Analysis]
11 Aukrust SG, Holte KB, Opstad TB, Seljeflot I, Berg TJ, Helseth R. NETosis in Long-Term Type 1 Diabetes Mellitus and Its Link to Coronary Artery Disease. Front Immunol 2021;12:799539. [PMID: 35069582 DOI: 10.3389/fimmu.2021.799539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Spaetgens B, Nagy M, Ten Cate H. Antiplatelet Therapy in Patients With COVID-19-More Is Less? JAMA 2022;327:223-4. [PMID: 35040901 DOI: 10.1001/jama.2021.23866] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Al-Najjar BO, Saqallah FG, Abbas MA, Al-Hijazeen SZ, Sibai OA. P2Y12 antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies. Eur J Med Chem 2022;227:113924. [PMID: 34731765 DOI: 10.1016/j.ejmech.2021.113924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Langer I, Latek D. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors. Front Endocrinol (Lausanne) 2021;12:711906. [PMID: 34867774 DOI: 10.3389/fendo.2021.711906] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Schmidt SN, Reichardt W, Kaufmann BA, Wadle C, von Elverfeldt D, Stachon P, Hilgendorf I, Wolf D, Heidt T, Duerschmied D, Peter K, Bode C, von Zur Mühlen C, Maier A. P2Y12 Inhibition in Murine Myocarditis Results in Reduced Platelet Infiltration and Preserved Ejection Fraction. Cells 2021;10:3414. [PMID: 34943922 DOI: 10.3390/cells10123414] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Vieira Corrêa PCM, Carneiro DM, da Silva Valente LDS, Diogo FM, Lamarão LM, da Silva Maués JH, Moreira-Nunes CA, Burbano RMR. Detection of Sepsis in Platelets Using MicroRNAs and Membrane Antigens. Genes (Basel) 2021;12:1877. [PMID: 34946826 DOI: 10.3390/genes12121877] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Zarei M, Sahebi Vaighan N, Ziai SA. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19. Immunopharmacol Immunotoxicol 2021;43:633-43. [PMID: 34647511 DOI: 10.1080/08923973.2021.1988102] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Palacios-Acedo AL, Mezouar S, Mège D, Crescence L, Dubois C, Panicot-Dubois L. P2RY12-Inhibitors Reduce Cancer-Associated Thrombosis and Tumor Growth in Pancreatic Cancers. Front Oncol 2021;11:704945. [PMID: 34589424 DOI: 10.3389/fonc.2021.704945] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
19 Shao BZ, Yao Y, Li JP, Chai NL, Linghu EQ. The Role of Neutrophil Extracellular Traps in Cancer. Front Oncol 2021;11:714357. [PMID: 34476216 DOI: 10.3389/fonc.2021.714357] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
20 Siegel PM, Sander L, Fricke A, Stamm J, Wang X, Sharma P, Bassler N, Ying YL, Olivier CB, Eisenhardt SU, Bode C, Ahrens I, Diehl P, Peter K. P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells. Sci Rep 2021;11:17459. [PMID: 34465804 DOI: 10.1038/s41598-021-95710-3] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
21 Li F, Xu D, Hou K, Gou X, Li Y. The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells. J Thromb Thrombolysis 2020;50:874-85. [PMID: 32248335 DOI: 10.1007/s11239-020-02098-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
22 Luo L, Zhang J, Lee J, Tao A. Platelets, Not an Insignificant Player in Development of Allergic Asthma. Cells 2021;10:2038. [PMID: 34440807 DOI: 10.3390/cells10082038] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Kim SH, Trinh HKT, Park HS, Shin YS. The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma. Clin Mol Allergy 2021;19:11. [PMID: 34256766 DOI: 10.1186/s12948-021-00149-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Luo Q, Liu R, Qu K, Liu G, Hang M, Chen G, Xu L, Jin Q, Guo D, Kang Q. Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17. Eur J Med Res 2021;26:70. [PMID: 34229761 DOI: 10.1186/s40001-021-00536-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Ekowati J, Febriani K, Yaqin INA, Wulandari AA, Mulya IH, Nofianti KA, Syahrani A. Shallot skin profilling, computational evaluation of physicochemical properties, ADMET, and molecular docking of its components against P2Y12 receptor. J Basic Clin Physiol Pharmacol 2021;32:429-37. [PMID: 34214369 DOI: 10.1515/jbcpp-2020-0470] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Shen X, Cao K, Zhao Y, Du J. Targeting Neutrophils in Sepsis: From Mechanism to Translation. Front Pharmacol 2021;12:644270. [PMID: 33912055 DOI: 10.3389/fphar.2021.644270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
27 Gómez Morillas A, Besson VC, Lerouet D. Microglia and Neuroinflammation: What Place for P2RY12? Int J Mol Sci 2021;22:1636. [PMID: 33561958 DOI: 10.3390/ijms22041636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
28 von Kügelgen I. Molecular pharmacology of P2Y receptor subtypes. Biochem Pharmacol 2021;187:114361. [PMID: 33309519 DOI: 10.1016/j.bcp.2020.114361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
29 Pavlović N, Kopsida M, Gerwins P, Heindryckx F. Inhibiting P2Y12 in Macrophages Induces Endoplasmic Reticulum Stress and Promotes an Anti-Tumoral Phenotype. Int J Mol Sci 2020;21:E8177. [PMID: 33142937 DOI: 10.3390/ijms21218177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Sriram K, Insel PA. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev 2021;101:545-67. [PMID: 33124941 DOI: 10.1152/physrev.00035.2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
31 Fakhrudin N, Pertiwi KK, Takubessi MI, Susiani EF, Nurrochmad A, Widyarini S, Sudarmanto A, Nugroho AA, Wahyuono S. A geranylated chalcone with antiplatelet activity from the leaves of breadfruit (Artocarpus altilis). PHAR 2020;67:173-80. [DOI: 10.3897/pharmacia.67.e56788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Pissarek M. Positron Emission Tomography in the Inflamed Cerebellum: Addressing Novel Targets among G Protein-Coupled Receptors and Immune Receptors. Pharmaceutics 2020;12:E925. [PMID: 32998351 DOI: 10.3390/pharmaceutics12100925] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Li Y, Zhang Y, Cao B, Zhang F, Niu M, Bai X, Zhang M, Zhang H. Screening for the antiplatelet aggregation quality markers of Salvia yunnanensis based on an integrated approach. Journal of Pharmaceutical and Biomedical Analysis 2020;188:113383. [DOI: 10.1016/j.jpba.2020.113383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
34 Oikonomou E, Leopoulou M, Theofilis P, Antonopoulos AS, Siasos G, Latsios G, Mystakidi VC, Antoniades C, Tousoulis D. A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. Atherosclerosis 2020;309:16-26. [PMID: 32858395 DOI: 10.1016/j.atherosclerosis.2020.07.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
35 Wirsching E, Fauler M, Fois G, Frick M. P2 Purinergic Signaling in the Distal Lung in Health and Disease. Int J Mol Sci 2020;21:E4973. [PMID: 32674494 DOI: 10.3390/ijms21144973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]